ReviewInternational journal of experimental pathology2002
The biology of the combretastatins as tumour vascular targeting agents.
Review in International journal of experimental pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 335 citations in OpenAlex.
- Natural Compounds as Epimodulators in Epithelial Ovarian Cancer.Epigenomes · 2026Review
- Cytotoxic Activity of Chemical Constituents ofPlants (Basel, Switzerland) · 2025Article
- Precise photopharmacological eradication of metastatic tumor cells.Disease models & mechanisms · 2025Article
- Design, Synthesis and Biological Evaluation of 2-Phenyl Indole Analogues of OXi8006 as Colchicine Site Inhibitors of Tubulin Polymerization and Vascular Disrupting Agents.Bioorganic & medicinal chemistry · 2025Article
- Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells.bioRxiv : the preprint server for biology · 2025Article
- Design, synthesis and evaluation of dihydro-1Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Multifunctional nanostructures: Intelligent design to overcome biological barriers.Materials today. Bio · 2023Review
- CuI-mediated synthesis of 1-aryl-5,6,7-trimethoxybenzimidazoles as potent antitubulin agents.RSC advances · 2023Article
- The use of African medicinal plants in cancer management.Frontiers in pharmacology · 2023Review
- Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation.International journal of molecular sciences · 2022Review
- Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes.Acta pharmaceutica Sinica. B · 2022Article
- Vasohibin 1 selectively regulates secondary sprouting and lymphangiogenesis in the zebrafish trunk.Development (Cambridge, England) · 2021Article
- Photocontrolled activation of small molecule cancer therapeutics.RSC medicinal chemistry · 2020Review
- Nanotechnology for angiogenesis: opportunities and challenges.Chemical Society reviews · 2020Review
- Biological Evaluation of a Potential Anticancer Agent MethylCancer biotherapy & radiopharmaceuticals · 2020Article
- Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review.Pharmaceuticals (Basel, Switzerland) · 2020Review
- The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression.Advances in experimental medicine and biology · 2020Review
- Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues.MedChemComm · 2019Article
- Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity.RSC advances · 2019Article
- Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice.Frontiers in pharmacology · 2019Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumour vasculature is an attractive target for therapy. Combretastatin A-4 (CA-4) and A-1 (CA-1) are tubulin binding agents, structurally related to colchicine, which induce vascular-mediated tumour necrosis in animal models. CA-1 and CA-4 were isolated from the African bush willow, Combretum caffrum, and several synthetic analogues are also now available, such as the Aventis Pharma compound, AVE8062. More soluble, phosphated, forms of CA-4 (CA-4-P) and CA-1 (CA-1-P) are commonly used for in vitro and in vivo studies. These are cleaved to the natural forms by endogenous phosphatases and are taken up into cells. The lead compound, CA-4-P, is currently in clinical trial as a tumour vascular targeting agent. In animal models, CA-4-P causes a prolonged and extensive shut-down of blood flow in established tumour blood vessels, with much less effect in normal tissues. This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.